Updating CAR-T Cell Immunotherapy for Liquid and Solid Tumor

According to the GLOBOCAN 2020 report, there is still a 50% mortality rate observed in cancer patients despite the availability of various innovative cancer therapies. This highlights the need for specific therapies that can effectively kill cancer cells without harming normal cells. One such therapy is cancer immunotherapy, which comprises immune checkpoint blockade, adoptive cellular therapies, cancer vaccines, and CAR-T cell therapy. CAR-T cell therapy entails modifying T-cells from a cancer patient in a lab so that they attack cancer cells only. This therapy has been successful in treating some lymphomas and myelomas, and is being explored for solid tumors as well. However, there are certain limitations to its efficacy for solid tumors due to their heterogeneity. This review covers the most recent advancements and enhancements in CAR-T therapies for lymphomas and solid tumors, as well as methods to get around their drawbacks.